Phase II study of rituximab plus pembrolizumab (MK-3475) in subjects with relapsed follicular lymphoma
The goal of this clinical research study is to learn if the combination of pembrolizumab and rituximab can help to control relapsed follicular lymphoma (FL). The safety of this drug combination will also be studied.
Treatment Location: N/A
IRB Review and Approval Date: 07/31/2015
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: